Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Immunomedics, Inc.
Gilead aims to launch its key oncology product Trodelvy by 2024 in Japan while building a dedicated business unit for oncology in the firm’s Japanese office. The firm has expanded its exclusive rights for oncology products in APAC.
Hopes are rising that Johnson & Johnson will be able to emulate AbbVie’s success in delaying US biosimilar competition to its top-selling Humira by using a similar settlement strategy with its anti-IL12/IL23 blockbuster Stelara.
In Trop2 Merck & Co. might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.
Clinical concerns outweigh quality issues in big pharma CRLs, a Pink Sheet analysis finds, making mirikizumab – the fourth new product candidate sponsored by Lilly to receive a CRL since 2021 – even more of an outlier: it was turned back by FDA because of manufacturing concerns.
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- IBC Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.